VR Adviser
Latest statistics and disclosures from VR Adviser's latest quarterly 13F-HR filing:
- Top 5 stock holdings are APGE, ORKA, VRDN, SYRE, KALV, and represent 55.18% of VR Adviser's stock portfolio.
- Added to shares of these 8 stocks: SYRE (+$33M), HELP (+$31M), VOR (+$19M), MAZE (+$13M), CBIO (+$8.8M), SVRA (+$6.4M), ZURA, DNTH.
- Started 1 new stock position in HELP.
- Reduced shares in these 10 stocks: MTSR (-$196M), CDTX (-$91M), COGT (-$71M), OCUL (-$71M), ABVX (-$49M), Astria Therapeutics (-$18M), PHVS (-$17M), PCSC (-$8.0M), ORIC (-$7.5M), TENX.
- Sold out of its positions in ABVX, Astria Therapeutics, CDTX, MTSR, TENX, PCSC, PHVS.
- VR Adviser was a net seller of stock by $-417M.
- VR Adviser has $2.0B in assets under management (AUM), dropping by 13.95%.
- Central Index Key (CIK): 0001615982
Tip: Access up to 7 years of quarterly data
Positions held by VR Adviser consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for VR Adviser
VR Adviser holds 27 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Apogee Therapeutics (APGE) | 31.7 | $641M | 8.5M | 75.48 |
|
|
| Oruka Therapeutics (ORKA) | 6.2 | $126M | 4.1M | 30.31 |
|
|
| Miragen Therapeutics (VRDN) | 6.0 | $121M | 3.9M | 31.12 |
|
|
| Spyre Therapeutics Com New (SYRE) | 6.0 | $121M | +37% | 3.7M | 32.76 |
|
| Kalvista Pharmaceuticals (KALV) | 5.4 | $109M | 6.7M | 16.15 |
|
|
| Ocular Therapeutix (OCUL) | 4.4 | $89M | -44% | 7.3M | 12.14 |
|
| Savara (SVRA) | 4.1 | $83M | +8% | 14M | 6.03 |
|
| Cogent Biosciences (COGT) | 3.5 | $71M | -50% | 2.0M | 35.52 |
|
| Erasca (ERAS) | 3.3 | $66M | 18M | 3.72 |
|
|
| Cytomx Therapeutics (CTMX) | 3.3 | $66M | 16M | 4.26 |
|
|
| Maze Therapeatics (MAZE) | 3.2 | $64M | +25% | 1.5M | 41.43 |
|
| Jade Biosciences Com New (JBIO) | 2.5 | $50M | 3.2M | 15.43 |
|
|
| Enliven Therapeutics (ELVN) | 2.5 | $50M | 3.2M | 15.40 |
|
|
| Oric Pharmaceuticals (ORIC) | 2.3 | $46M | -13% | 5.7M | 8.18 |
|
| Engene Holdings (ENGN) | 2.1 | $43M | -5% | 4.8M | 9.03 |
|
| Dyne Therapeutics (DYN) | 2.1 | $43M | 2.2M | 19.56 |
|
|
| Dianthus Therapeutics (DNTH) | 2.0 | $41M | +4% | 1.0M | 41.21 |
|
| Upstream Bio (UPB) | 1.6 | $32M | 1.2M | 27.15 |
|
|
| Cybin Com New (HELP) | 1.6 | $31M | NEW | 3.8M | 8.18 |
|
| Zura Bio Class A Ord Shs (ZURA) | 1.4 | $28M | +15% | 5.3M | 5.24 |
|
| Vor Biopharma Com New (VOR) | 1.3 | $25M | +288% | 1.9M | 13.08 |
|
| Crescent Biopharma (CBIO) | 1.2 | $25M | +53% | 2.1M | 11.86 |
|
| Septerna (SEPN) | 0.8 | $17M | 611k | 27.88 |
|
|
| Surrozen Com New (SRZN) | 0.7 | $14M | 633k | 22.60 |
|
|
| Cullinan Oncology (CGEM) | 0.7 | $14M | 1.4M | 10.35 |
|
|
| Artiva Biotherapeutics (ARTV) | 0.3 | $6.9M | 1.6M | 4.29 |
|
|
| Casi Pharmaceuticals Ord Shs (CASI) | 0.0 | $839k | 987k | 0.85 |
|
Past Filings by VR Adviser
SEC 13F filings are viewable for VR Adviser going back to 2020
- VR Adviser 2025 Q4 filed Feb. 17, 2026
- VR Adviser 2025 Q3 filed Nov. 14, 2025
- VR Adviser 2025 Q2 filed Aug. 14, 2025
- VR Adviser 2025 Q1 filed May 15, 2025
- VR Adviser 2024 Q4 filed Feb. 14, 2025
- VR Adviser 2024 Q3 filed Nov. 14, 2024
- VR Adviser 2024 Q2 filed Aug. 14, 2024
- VR Adviser 2024 Q1 filed May 15, 2024
- VR Adviser 2023 Q4 filed Feb. 14, 2024
- VR Adviser 2023 Q3 filed Nov. 14, 2023
- VR Adviser 2023 Q2 filed Aug. 11, 2023
- VR Adviser 2022 Q2 restated filed May 15, 2023
- VR Adviser 2022 Q3 restated filed May 15, 2023
- VR Adviser 2022 Q4 restated filed May 15, 2023
- VR Adviser 2023 Q1 filed May 15, 2023
- VR Adviser 2022 Q4 filed Feb. 14, 2023